3D bioprinted poly(lactic acid)/mesoporous bioactive glass based biomimetic scaffold with rapid apatite crystallization and in-vitro Cytocompatability for bone tissue engineering.

In the recent years, bone tissue engineering is regarded as the promising solution for treatment of bone defects which arises due to trauma, infection and surgical intervention. In view of this, several polymer or ceramic based constructs are envisaged for bone tissue engineering potential. However, scaffolds based on pure polymeric materials suffer from slow bioactivity characteristics. On the other hand, scaffolds based on ceramic materials do not offer sufficient strength for load bearing applications. In order to overcome these drawbacks, the current work aims to develop mixed matrix scaffolds based on poly (L-lactic acid)/mesoporous bioactive glass composite with the formulation of 30:70 weight ratio, which mimics the natural bone composition. In the current work, PLA/MBG (30:70) composite based bioink suitable for 3D bioprinting is indigenously developed and its rheological characteristics are evaluated. The 3D architecture for PLA/MBG composite scaffold is designed using Solidworks CAD 2015 and the scaffolds are fabricated using pneumatic based 3D bioprinting technology, which has not been documented earlier for this formulation in view of bone tissue engineering in the best of our knowledge. Followed by this, optimization of printing parameters in order to develop 3D PLA/MBG composite constructs with hierarchical pore architecture suitable for bone tissue engineering is performed. The SEM analysis confirmed that the pore size of the 3D printed PLA/MBG composite scaffolds falls in the range of 500-700 μm, which corresponds to the macroporous nature of the scaffolds useful for bone cell growth. The mechanical analysis confirmed the superior compressive modulus and yield strength for PLA/MBG composite scaffold in comparison with neat PLA. The in-vitro bioactivity assessment showed rapid apatite crystallization by attaining Ca/P ratio of 1.66 equivalent to natural bone mineral within 3rd day of SBF treatment for PLA/MBG composite scaffold, thus indicating the excellent bioactivity behaviour. The 3D bioprinted PLA/MBG composite scaffold showed promising response in terms of cell attachment and proliferation, mineralization as well as gene expression characteristics while assessed through of in-vitro biological assessment using MG-63 osteosarcoma cells. In this regard, the 3D bioprinted PLA/MBG scaffold could be applied as potential implant for bone tissue engineering application.